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Edited by Lukas HuberAbstract Histamine is known to act, at least in part, as a
growth factor for several cell types, and as production of this bio-
gen amine has been found to accelerate the rate of tissue prolif-
eration in wound repair, embryogenesis and malignant growth.
Abundant experimental and clinical data suggest that histamine
augments in vivo tumour cell proliferation via histamine H2
receptors (H2R). Here, we report that exogenously added hista-
mine stimulates Ets-1(v-ets erythroblastosis virus E26 oncogene
homolog 1) synthesis in human melanoma cells. Involvement of
histamine receptors in the histamine induced ets-1 expression
has been also studied. Our data show that these newly recognized
actions of histamine are mediated by the H2R. Modiﬁcation of
local protooncogen Ets-1 level is likely being involved in the reg-
ulation of melanoma growth.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Protooncogen1. Introduction
Histidine-decarboxylase has been detected in many tissues
and cells [1,27]. It has also been shown that the level of histi-
dine decarboxylase (HDC) mRNA and HDC activity increases
in proliferating tissues. High HDC level was found during
embryonic development and in tumour cells [2]. Histamine ex-
erts its function through binding to G-protein associated H1,
H2, H3, H4 receptors resulting in activation of diﬀerent signal
transduction pathways [3]. Our previous data showed that in a
primary melanoma cell line endogenous histamine acts
through H2 receptor (H2R) as an autocrine growth factor
resulting in elevated cell proliferation [4].
The H2Rs are coupled to both adenylate cyclase and phos-
phoinositide second messenger systems. In addition, these
receptors regulate c-fos and c-jun expression by diﬀerent path-
ways involving PKC and other kinases [28].
The Ets family of transcription factors is comprised of pro-
teins that share a unique DNA binding ETS domain. The pro-
tooncogen Ets-1 is known to control the expression of several
genes involved in extracellular matrix (ECM) remodeling, cell
migration and tumour invasion [5,6]. The level of Ets-1 expres-
sion in epithelial tumor cells was correlated with the progres-*Corresponding author. Fax: +36 1 303 6968.
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cell diﬀerentiation. In addition, Ets-1 expressing cells were lo-
cated at the invasive front of the tumor. This is consistent with
previous observations that Ets-1 was associated with branch-
ing morphogenesis and organ formation in embryos [7] and
embryonic stem cell diﬀerentiation. Increased expression of
genes encoding enzymes involved in degradation of the
ECM, such as MMP-1 (collagenase-1), MMP-3 (stromelysin-
1), MMP-7 (matrilysin), and MMP-9 (type IV collagenase/gel-
atinase) has been identiﬁed in cancer from recent microarray
data [8].
Hence, Ets-1 is likely to contribute to tumor invasion and
progression through activation of these enzymes. Indeed,
expression of these ECM remodeling enzymes was concomi-
tantly detected with Ets-1 mRNA in tumour cells and/or stro-
ma cells. Ets-1 is also involved in angiogenesis, essential for
tumor progression. In a non-vascularized tumor the growing
tumor becomes ischaemic, thus the observation that Ets-1 in-
duced by hypoxia via hypoxia-inducible factor-1 (HIF-1) [9]
suggests the relevance of Ets-1 in vascularization. Moreover,
both vascular endothelial growth factor (VEGF) and basic
ﬁbroblast growth factor (bFGF) induce Ets-1 in endothelial
cells. Ets-1 was believed to confer an angiogenic phenotype
to the endothelial cells through induction of the urokinase-type
plasminogen activator (u-PA) and matrix metalloproteinases
(MMPs), and also to regulate N-acetylglucosaminyl-transfer-
ase V (GnT-V), which has been associated with metastasis of
tumors [10]. Thus, the microenvironment of a growing tumor
may induce Ets-1 in tumor cells and/or stroma cells, which
subsequently induces angiogenesis-related genes and ECM
remodeling enzymes required for tissue invasion and metasta-
sis. It is important to note that expression of Ets-1 in both
tumor and stroma was correlated with poor prognosis in
human ovarian carcinoma. Although semi-quantitative RT-
PCR technology represents a signiﬁcant advance in assay
quantiﬁcation, the precise amount and quality of RNA are
still diﬃcult to assess. To address this problem, we used a re-
verse transcription comparative real-time PCR method,
which also quantiﬁes transcripts of an endogenous gene as
an RNA internal control. We used the value from the control
to calibrate levels of H1R, H2R, H3R, H4R and Ets-1
expression in paired normal melanocyte and four diﬀerent
human melanoma cell lines. Furthermore, we addressed the
question whether histamine is involved in the regulation of
ets-1 expression in melanoma cells and what is the receptor
speciﬁcity of this action.blished by Elsevier B.V. All rights reserved.
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2.1. Cell lines
The HT-168 and the HT-168/M1 melanoma lines are a derivate of
the A2058 cell line selected for high metastasing capacity in immunosu-
pressed CBA/Ca mice. The A2058 melanoma cell line was derived orig-
inally from brain metastasis. The WM983B line, derived from cutan
metastasis, and WM35 was isolated from an early stage primary lesion.
Human melanoma cell lines: HT168, HT168-M1, VM35 and WM983/
B were kindly provided by Dr. J. Tı´ma´r (National Institute of Oncol-
ogy, Budapest, Hungary) were cultured on RPMI-1640 medium sup-
plemented with 10% FCS.
Human melanocyte provided by A. Pivarcsi (Univ. of Szeged, Hun-
gary) was isolated from dispase-treated skin from a young women and
treated with trypsin for 5 min. Dispersed cells were cultured in kerati-
nocyte growth media (Clonetics, San Diego) for 2–3 days, then grown
in melanocyte selective media (Cascade Biologics, Portland, OR). Mel-
anocytes were counted based on their morphology and pigmentation.
The cells were treated with either medium or with 1 lM histamine
(Sigma), 1 lM H1 agonist HTMT-dimaleate, or 1 lM H2 agonist
dimaprit, (Tocris, UK), 1 lM H3 agonist UCL 1470-H-7 kindly pro-
vided by Prof. C.R. Ganellin (University College London, UK), or
0.1 lM dibutiryl-cAMP (dBcAMP, Sigma).2.2. Semiquantitative RT-PCR studies for histamine-receptor subtypes
Total cellular RNA was prepared by TRI-reagent (Sigma) according
to the protocol, and RNA was treated by RNAse free DNAase (Pro-
mega). A total 2 lg RNA was added to the RT reaction mixture (40 ll)
in the presence of random hexamers and the samples were incubated at
42 C for 30 min and 99 C for 5 min.
The speciﬁc primers were:
for human H1R: TGGTCACAGTAGGGCTCAAC and CAAGGT-
GGGCAGGTAGAAGT,
for human H2R: TCGTGTCCTTGGCTATCAC and CCTTGCTG-
GT-CTCGTTCCT,
for human H3R: GAGAAGCGCATGAAGATGGT and AGGAGC-
CAGAAGGAGGTTTC,
and for human ets-1: GGGTGACGACTTCTTGTTTG and GTTAA-
TGGAGTCAACCCAGC
as sense and antisense primers, respectively. The PCR products were
run on 2% agarose gel, and were visualized by ethidium-bromide.2.3. Realtime quantitative reverse transcriptase Q (RT)-PCR
Each of the four human tumor cell lines were grown to conﬂu-
ence in T75 ﬂasks suspended and lysed using TRIzol. Real-time
PCR for was performed with Universal PCR Master Mix using
PCR primers TaqMan Gene Expression Assays (Applied Biosys-
tems). QRT-PCR was carried out using a ABI Prism 7000 Sequence
Detection System (Applied Biosystems) and the associated ABI 2.0
software was used to analyze the data and determine the threshold
count (Ct) regarding relative quantiﬁcation of gene expression exper-
iments refer to ABI PRISM 7700 Sequence Detection System User
Bulletin §2 (P/N 4303859). Primers and probes were designed using
the Assays-on Demand gene expression product list of Applied Bio-
system.
Reaction mixtures for QRT-PCR were 25 ll, for all reactions, nega-
tive controls were run with no template present. Each sample was run
in triplicate, and Ct was determined for histamine receptors and Ets-1
and Hu-18S (rRNA as an internal control). We chose Hu-18S as the
housekeeping gene to which we normalized our specimens because it
is expressed in a relatively stable fashion in nearly every cell type
and is only weakly regulated. We chose it over other commonly used
housekeeping genes, particularly glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), because of recent evidence that GAPDH levels can
vary signiﬁcantly between individuals when compared with ß-actin,
making GAPDH inappropriate for experiments comparing gene
mRNA levels between individual samples.2.4. Detection of changes in Ets-1 content by ﬂow-cytometry
Ets-1 stored intracellularly in melanoma cells was monitored after
cell ﬁxation, partial cell permeabilization, and staining with an Ets-1
speciﬁc mAb (Santa-Cruz Biotechnology, Inc, US). Brieﬂy, 5–3 · 105
cells were ﬁxed at 4 C for 10 min in a mixture of 4% paraformalde-hyde. After intense washing, cells were permeabilized with 2 ml PBS
0.02% Saponin (Sigma). Thereafter, the Ets-1-speciﬁc polyclonal Ab
was added at a concentration of 1.5 lg/ll, and cells were once again
incubated for 30 min on room temperature. After washing, a second-
ary FITC-conjugated F (ab) fragment of goat anti-rabbit IgG antibod-
ies (BD Bioscience) was added at a concentration of 10 lg/ll, and cells
were incubated for an additional 30 min at 20 C. Finally, cells were
washed and ﬁxed in PBS containing freshly prepared 1% paraformal-
dehyde. At least 10 000 cells were analyzed using an FACS Calibur
(Beckton Dickinson) ﬂow cytometer [11]. Results were expressed as
percent positive cells, taking into account the amount of unspeciﬁc
binding of the corresponding isotype control antibody. The analysis
was performed by CellQuest 3.2 software.2.5. Western blot analysis
Whole-cell extracts were resolved by sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS–PAGE, 10% polyacrylamide).
Nitrocellulose membranes were used for transfer, and after being
blocked with 10% skim milk (99% fat free)–0.1% Tween 20-phosphate
buﬀer, membranes were probed with appropriate primary antibodies
(for 1 h to overnight at 24 C). Proteins were detected with peroxi-
dase-conjugated anti-rabbit immunoglobulin secondary antibody and
visualized with the ECL detection kit (Amersham).
Data were evaluated for statistical signiﬁcance by Students t test.
P < 0.05, as compared with untreated controls (n = 3).3. Results
3.1. Receptor expression
In order to determine whether the diﬀerences in histamine
responsiveness between the 4 melanoma cell lines resulted from
expression of diﬀerent receptor types, we applied the mRNAs
to RT-PCR to obtain the receptor expression proﬁle. In the
four melanoma cell lines there is a constitutive expression of
H1, H2, H3 receptors (Fig. 1A) and H3-receptor protein has
also been detected with polyclonal antibody (data not shown).
Our study demonstrates that H3 receptor is present not only on
well-characterised histamine-containing neurons, but on hu-
man melanoma cells, too. Others [12] found H3 receptors in
dendritic cells. As shown in Fig. 1B in the cells expressed a
higher amount of H2R than of H1 receptor. Histamine H3
receptor expression was very faintly detected in all cell lines.
We have conﬁrmed the receptor expression proﬁle in the
melanoma cells, by quantitative real-time RT-PCR. Before
QRT-PCR, mRNA samples were subjected to standard reverse
transcription-PCR with previously described primers to ampli-
fy histamine receptors and Ets-1. All cell lines were positive for
H1-, H2-, H3R and Ets-1.
Accuracy of PCR quantiﬁcation is accomplished by deter-
mining the point during cycling when ampliﬁcation of the
PCR product is ﬁrst detected, rather than the amount of prod-
uct accumulated after a ﬁxed number of cycles expressed as the
threshold of cycle number (Ct) at which the ﬂuorescence gen-
erated by cleavage of the probe passes a ﬁxed threshold above
baseline. Since this technology monitors the entire PCR reac-
tion by ﬂuorescence detection, the beginning of the exponential
phase of ampliﬁcation can be precisely measured. The switch
of the predominant histamine receptor type from H1 to H2
dependency from the metastatic capacity was clearly demon-
strated by this analysis. The histamine receptor proﬁle was
H2 dominant in the non-metastatic WM35 cells, while it
turned to be H1 dominant in the highly metastatic HT-168/
M1 cells (Fig. 1B). H4 receptor expression was not detected
in our experimental conditions (data not shown).
Fig. 2. (A) RT-PCR analysis of Ets-1 mRNA expression in four
human melanoma cell lines. The open arrow indicates the band
corresponding to Ets-1 PCR products. 1: WM35, 2: WM983/B, 3: HT-
168, 4: HT-168/M1. (B) Flow cytometric analysis of Ets-1 protein
expression after 24 h treatment with 1 lM histamine dihydrochloride
(HA) in human melanoma cells. Data are expressed as average of mean
ﬂuorescence ± S.E. \P < 0.05, \\P < 0.01 compared to untreated (con-
trol) cells. For isotype control similarly labelled preimmune rabbit IgG
was used.
Fig. 3. The eﬀect of dimaprit on Ets-1 mRNA expression in WM35
melanoma cell line. Cells were incubated with 106 M dimaprit. At
indicated time points, mRNA was isolated and QRT-PCR was
performed, each sample was run in triplicate. Ets-1 mRNA expression
was normalized to 18S RNS expression and expressed in arbitrary
units as described in Section 2. Each bar represents the means ± S.E.
for the measured Ets-1 levels in each group (n = 3 independent
experiments). There was a signiﬁcant diﬀerence between the means of
all treated groups in Ets-1 compared to the untreated group.
Fig. 1. (A) Histamine receptors were detected by RT-PCR (arrows
show the speciﬁc PCR products). 1: HT168/M1, 2: HT/168, 3: WM983/
B, 4: WM35, 5: Primary melanocyte. (B) Comparing the relative
expression of H1-, H2-, and H3R mRNA in four human melanoma
cell lines. Histamine receptor levels were measured using QRT-PCR,
and each sample was run in triplicate. The histamine receptors mRNA
expression was normalized to 18S RNA and expressed in arbitrary
units as each bar represents the means ± S.E. for the measured
histamine receptor levels in each group. The entire four cell lines
expressed H3R at four times higher levels comparable with the primary
normal melanocyte. H1R and H2R were expressed at variable levels in
the four cell lines: at a highest level of H2R and lowest level of H1R in
WM35; both at a modest level in WM983/B and HT-168; and at lower
level of H2R and higher level of H1R in HT-168/M1 were present. The
results were corrected for 18S rRNA and were expressed in arbitrary
units.
H. Hegyesi et al. / FEBS Letters 579 (2005) 2475–2479 24773.2. Eﬀect of histamine on Ets-1 expression
We have also examined gene expression of Ets-1 in four cell
lines (Fig. 2A) and the correlation between the elevated Ets-1
expression and stimulatory eﬀect of histamine has been found
in these cell lines. The responsiveness of ets-1 protein expres-
sion to histamine treatment analyzed by FACS and it was
the highest in the WM 35 cells (Fig. 2B).
3.3. Histamine-enhanced Ets-1 activation acts on H2 receptor
To address whether histamine transcriptionally upregulates
the ets-1 gene in the WM35 cells through the cAMP signal
transduction pathway, we measured the change of Ets-1
mRNA. Speciﬁc H2R antagonist, dimaprit, which time-
dependently enhanced the Ets-1 gene activity, studied receptor
speciﬁcity of the histamine on Ets-1.
1 lM dimaprit induced Ets-1 message levels were determined
by QRT-PCR using TaqMan MGB (FAM dye labeled)
probes, as the 5 0-ﬂuorophore and a nonﬂuorescent quencher
at the 3 0 end of probe. The cultures were treated with dimaprit
(1 lM M) for either 30 min, 1, or 3 h. Ets-1 expression inWM35 rapidly increased following H2 agonist dimaprit stimu-
lation, showing 6-fold augmentation over 0-time controls at
30 min of 1 lM dimaprit exposure which decreased half of it
at 1 h and at 3 h (Fig. 3). The H2R is assumed to trigger the
Gas protein, which in turn stimulates adenylate cyclase and
the synthesis of cAMP. If the observed interaction of histamine
with Ets-1 activation is mediated by the H2R, the enhancing
eﬀect of histamine could be sensitive to an adenylate cyclase
inductor, such us dB-cAMP. Dibutylic cAMP (dB-cAMP)
treatment caused elevated Ets-1 expression. To study whether
H2R induced signal cascade is involved in the mechanism of
Fig. 4. Flow cytometric analysis the eﬀect of histamine dihydrochlo-
ride (1 lM), or H2 agonist, dimaprit (1 lM), or dBcAMP (0.1 lM) on
Ets-1 production in WM35 and WM983/B melanoma cells. Data were
analysed by Students t test, and represented as means ± S.D.
\\P < 0.05, \P < 0.01; ANOVA.
Fig. 5. Western-blot analysis of Ets-1 expression after 24 h treatment
with histamine-dihydrochloride (106 M or 107 M) or with dimaprit
(105 M, 106 M, 107 M) in WM35 melanoma cells. The open arrow
indicates the band corresponding to Ets-1 protein.
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The melanoma cells treated with 1 lM histamine, or 1 lM H2
agonists (dimaprit) or 100 nM dB-cAMP showed a remarkable
increase in Ets-1 protein expression level after 24 h. The signal
transduction pathway triggered by elevated cAMP would be
well preserved in either condition of the melanoma cells, since
histamine and dB-cAMP up-regulated ets-1 mRNA expression
in all cell lines (Fig. 4).
As shown in Fig. 5, the cAMP-elevating agents including
histamine and H2R agonist dimaprit increased the amount
of Ets-1. Identical experiments carried out in the presence of
1 lM H1 or H3 agonists showed no eﬀect on the level of
Ets-1 protein (data not shown). These results suggest that
the histamine-dependent upregulation of Ets-1 synthesis of
the melanoma is mediated predominantly by H2R.4. Discussion
We investigated the role of the protooncogen transcription
factor Ets-1 as a mediator of the histamine action. The present
data clearly demonstrate that histamine, a ubiquitously occur-
ring local hormone, can function as a growth promoting factor
for cells types that express active H2 type receptors. Previously
were detected that in melanoma cells, histamine acting through
the H1 receptor decreases cell proliferation, whereas it en-
hances growth when acting through H2R [13]. Here, we found
no evidence that mitogenic signaling through H3 type recep-
tors may involve alterations of the proliferation of human mel-
anoma cells. Our results raise the intriguing possibility of a role
for histamine in promoting cell growth and migration via ets-1
mediated way.Ets-1 is produced by a variety of solid tumors, including epi-
thelial tumors, sarcomas and astrocytomas. Dependent on the
tumor type, Ets-1 expression is either increased or exclusively
found in invasive higher-grade tumors. High Ets-1 levels in
breast, ovary and cervix carcinoma correlates with poor prog-
nosis [14–16], appearing as an independent prognostic marker
of breast cancer not linked to other tumor markers, such as no-
dal status, tumor size, histological grade or estrogen receptor
status. In lung, colorectal and squamous cell carcinoma, Ets-
1 expression was associated with a higher incidence of lymph
node metastasis [17–19].
Ets-1 expression can be modulated by a variety of factors.
The human Ets-1 promoter is a TATA-less promoter contain-
ing both positive and negative regulatory elements [20]. Syn-
thesis is induced by HGF (hepatocyte growth factor), PDGF
(platelet-derived growth factor) or TNFa (tumor necrosis fac-
tor a) via activation of the Ras/Raf/MEK1/ERK1/2 pathway
[21].
The Ets-1 transcription factor plays a role in tumor vascular-
ization and invasion by regulating expression of matrix-
degrading proteases in endothelial cells and ﬁbroblasts in the
tumor stroma. During early embryogenesis, Ets-1 is expressed
in migrating neural crest cells from which melanocytes arise.
Expression of several Ets-1 target genes is known to be in-
volved in invasion, such as MMP1, MMP3, and uPA and inte-
grin b3. The invasive potential of the melanoma cells measured
in migration experiment was reduced up to 60% after Ets-1
blockade [22]. This can be attributed to the role of Ets-1 in
transcriptional regulation of factors involved in invasion of
melanoma cells.
Tumour progression, invasion, and metastasis are, clinically,
even more relevant than tumour induction. It is well known
that the outcome of tumour invasion and metastasis is closely
dependent on the capability of inducing angiogenesis.
Angiogenesis is tightly regulated by pro- and anti-angiogenic
factors. Secreting mast cells are able to induce and enhance
angiogenesis via multiple in part interacting pathways. In tu-
mour models, mast cells have been shown to play a decisive
role in inducing the angiogenic switch, which precedes malig-
nant transformation. In fact, it is well documented that hepa-
rin, combined with a range of heparin-binding factors such as
bFGF or TGFb (transforming growth factor) is able to pro-
mote neovascularisation, and that mast cell proteases cause
cell structural alterations by destroying the ECM integrity.
There is, moreover, strong evidence that mast cells signiﬁcantly
inﬂuence angiogenesis and thus growth and progression in hu-
man cancers [23], as well. The role of histamine secreted by
mast cells is less clear. It seems that histamine can behave as
a pro- or an anti-angiogenic modulator, depending on the sub-
type of local histamine receptor/s to which it binds.
Earlier it has been reported that histamine increases endo-
thelial cell proliferation via both H1 and H2Rs. Histamine
has an activity to induce VEGF production in the granulation
tissue via the H2R-cyclic AMP-protein kinase A pathway and
augments angiogenesis in the granulation tissue [24]. Recently
it has been demonstrated that HDC (/) mice show signiﬁ-
cantly lower VEGF levels in the granulation tissue and that
there is notably less angiogenesis and granulation tissue forma-
tion compared to the wild type. The topical injection of hista-
mine or the H2 agonist dimaprit rescued the defective
angiogenesis and granulation tissue formation in HDC (/)
mice. This eﬀect is not observed in mast cell deﬁcient mice.
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to express HDC. These ﬁndings indicate that histamine derived
from non-mast cells plays a signiﬁcant role in the angiogenesis
of the inﬂammatory granulation tissue [25]. Interferon-induced
protein of 10 kDa, IP-10, induces antitumour immune re-
sponses in synergy with IL-12 via activated Th1 cells. In addi-
tion, IP-10 inhibits tumour angiogenesis and abrogates a route
for nutrition and metastasis. Tumour cells can produce IP-10
in response to IFNc and histamine inhibits this eﬀect. In diﬀer-
ent melanoma and squamous carcinoma cell lines, it was ob-
served that histamine suppresses IP-10 secretion and mRNA
expression via H2R and the camp-protein kinase A signaling
pathway. By this mechanism histamine released from tumour
cells or peritumoural mast cells may increase angiogenesis
and sustain the growth and survival of tumour [26]. Our pres-
ent data indicate that locally produced histamine acting
through paracrine and autocrine way may elevate Ets-1 expres-
sion and a novel histamine Ets-1 pathway can be suggested in
the complex regulation of melanoma growth.
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